Clinical Trial Update: Ixazomib for Desensitization [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ixazomib for desensitization in kidney disease patients was completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• ixazomib (ixazomib)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Kidney Diseases, End Stage Renal Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-05-11